Decreased Plasma Tissue Factor Pathway Inhibitor Activity in Ischemic Stroke Patients

Takeo Abumiya; Takenori Yamaguchi; Tadashi Terasaki; Toshinori Kokawa; Kazuomi Kario; Hisao Kato

doi:10.1055/s-0038-1649880

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1995; 74(04): 1050-1054
DOI: 10.1055/s-0038-1649880

Original Article

Clinical Studies

Schattauer GmbH Stuttgart

Decreased Plasma Tissue Factor Pathway Inhibitor Activity in Ischemic Stroke Patients

Authors

Takeo Abumiya

¹The Research Institute Suita, Department of Medicine, National Cardiovascular Center, Suita, Osaka
Takenori Yamaguchi

²The Cerebrovascular Division, Department of Medicine, National Cardiovascular Center, Suita, Osaka
Tadashi Terasaki

²The Cerebrovascular Division, Department of Medicine, National Cardiovascular Center, Suita, Osaka
Toshinori Kokawa

¹The Research Institute Suita, Department of Medicine, National Cardiovascular Center, Suita, Osaka
Kazuomi Kario

³The Department of Internal Medicine, Awaji-Hokudan Public Clinic, Hokudan, Hyogo, Japan
Hisao Kato

¹The Research Institute Suita, Department of Medicine, National Cardiovascular Center, Suita, Osaka

Abstract

PDF Download

Summary

Although tissue factor pathway inhibitor (TFPI) plays an essential role in the regulation of blood coagulation, the quantitative changes in its levels in thrombotic disease are still undefined. We compared TFPI activity in ischemic stroke patients and control subjects matched for age and cholesterol level to determine whether TFPI activity is changed in the disease. TFPI activity was significantly lower in the stroke patients (1.01 ± 0.24 U/ml) than in the control subjects (1.10 ± 0.16 U/ml). In relation to clinical subtypes of stroke, TFPI activity in atherothrombotic infarction (0.93 ± 0.19 U/ml) and lacunar infarction (0.99 ± 0.23 U/ml) was significantly lower than in the control subjects, whereas the level in cardioembolic infarction (1.16 ± 0.31 U/ml) was not. No relationship could be established between TFPI activity and other haemostatic parameters reflecting the production of thrombin/fibrin and the activation of fibrinolysis. These results may suggest that the moderately lower TFPI activity in stroke patients could be due to atherosclerotic changes rather than to consumptive coagulopathy.

PDF (1868 kb)

References

References
1 Broze GJ, Girard TJ, Novotny WF. The lipoprotein-associated coagulation inhibitor. In: Progress in Haemostasis and Thrombosis. Coller BS. ed. Philadelphia, PA: WB Saunders Co; 1990. 10 243-268
2 Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor- dependent blood coagulation. Thromb Haemost 1991; 66: 6-15
3 Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagulation Fibrinolysis 1992; 3: 439-449
4 Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. J Intern Med 1989; 225: 311-316
5 Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989; 72: 391-396
6 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-393
7 Moor E, Hamsten A, Karpe F, Båvenholm P, Blombäck M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 1994; 71: 707-712
8 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813
9 Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coagulation Fibrinolysis 1991; 2: 713-721
10 Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400
11 Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagulation Fibrinolysis 1991; 2: 425-433
12 Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 1991; 11: 138-145
13 Abumiya T, Nakamura S, Takenaka A, Takenaka O, Yoshitomi Y, Miyamoto S, Kimura T, Enjyoji K, Kato H. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler Thromb 1994; 14: 483-488
14 National Institute of Neurological Disorders and Stroke Ad Hoc Committe. Classification of cerebrovascular diseases III. Stroke 1990; 21: 637-676
15 Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Tissue factor pathway inhibitor activity in human plasma: Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vase Biol 1995; 15: 504-510
16 Kato H, Uchida K. Automated fluorogenic methods for the evaluation of the extrinsic coagulation reactions in human plasma. Thromb Res 1988; 50: 77-90
17 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
18 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products: An immunoassay using monoclonal antibodies. Thromb Haemost 1983; 50: 591-594
19 Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in a₂-plasmin inhibitor. Blood 1987; 69: 446-453
20 Takano K, Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute cardioembolic stroke. Stroke 1991; 22: 12-16
21 Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable state following acute ischemic stroke. Stroke 1992; 23: 194-198
22 Yamazaki M, Uchiyama S, Maruyama S. Alterations of haemostatic markers in various subtypes and phases of stroke. Blood Coagulation Fibrinolysis 1993; 4: 707-712
23 Tohgi H, Kawashima M, Tamura K, Suzuki H. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. Stroke 1990; 21: 1663-1667
24 Kilpatrick TJ, Matkovic Z, Davis SM, McGrath CM, Dauer RJ. Hematologic abnormalities occur in both cortical and lacunar infarction. Stroke 1993; 24: 1945-1950
25 Takano K, Yamaguchi T, Okada Y, Uchida K, Kisiel W, Kato H. Hypercoagulability in acute ischemic stroke: Analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method. Thromb Res 1990; 58: 481-491
26 Yasaka M, Yamaguchi T, Miyashita M, Park YD, Sawada T, Omae T. Predisposing factors of recurrent embolization in cardiogenic cerebral embolism. Stroke 1990; 21: 1000-1007
27 Yasaka M, Yamaguchi T, Oita J, Sawada T, Shichiri M, Omae T. Clinical features of recurrent embolization in acute cardioembolic stroke. Stroke 1993; 24: 1681-1685